MONTREAL, Aug. 20 /CNW Telbec/ - Enobia Pharma, an emerging Canadian
biotech company focused on developing novel therapeutics for serious bone
disorders, today announced that the first patient in its clinical program for
hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement
Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling
genetic bone disorder for which there is no approved treatment.
